Vaderis Therapeutics
Develops an oral AKT inhibitor for hereditary hemorrhagic telangiectasia
$152MSeries B
Role not disclosedLoading investors…
Activity from announced rounds
Develops an oral AKT inhibitor for hereditary hemorrhagic telangiectasia
Develops antibody therapies to prevent seasonal influenza in high-risk and immunocompromised patients
Pitching EQT Life Sciences? Send the deck from a free RoundOS data room and see which pages they read.
Create a free room